Procept Biorobotics (NASDAQ:PRCT) is at the forefront of innovative healthcare solutions, focusing on developing and marketing advanced robotic technologies for the treatment of urological conditions. Their signature project, AquaBeam Robotic System, utilizes a groundbreaking approach to treating benign prostatic hyperplasia (BPH) by combining real-time imaging with robot-assisted waterjet ablation. This method underscores their objective to improve patient outcomes through minimally invasive procedures. By dedicating resources to research and development, Procept Biorobotics aims to extend its portfolio to include more state-of-the-art therapeutic solutions, thereby enhancing the quality of life for patients worldwide.